GlassScriptPhysician profile
Nnenna G Agim
NPI 1962603639
$39,126.75
in general payments reported to CMS, 2019-2025
21 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,188 · 2023: $171 · 2024: $8,256 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $3,972 · Travel and Lodging: $2,724 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,493.44 |
| Food and Beverage | $3,971.65 |
| Travel and Lodging | $2,723.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $29,917.68 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $4,592.14 | 2024 | Vtama |
| Genzyme Corporation | $1,546.99 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $750.00 | 2025 | Zoryve |
| Abbvie INC. | $538.24 | 2023-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $270.26 | 2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $262.45 | 2024-2025 | |
| Lilly USA, LLC | $249.41 | 2024-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $225.47 | 2023-2025 | Dupixent, Libtayo |
| Organon LLC | $222.16 | 2025 | Vtama, Nexplanon |
| Krystal Biotech INC | $152.06 | 2023-2025 | Vyjuvek |
| Novartis Pharmaceuticals Corporation | $103.79 | 2024-2025 | |
| Amgen INC. | $96.09 | 2024-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $32.38 | 2024-2025 | Ycanth |
| Integra Lifesciences Corporation | $28.73 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $28.55 | 2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $24.84 | 2024 | Sotyktu |
| Merz North America, INC. | $23.82 | 2024 | |
| Pfizer INC. | $22.07 | 2024 | |
| Leo Pharma INC. | $20.18 | 2025 | Anzupgo |
| Botanix Sb INC | $19.44 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nnenna Agim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.